KLOW Blend 80mg: KPV/GHK-Cu/BPC-157/TB-500 (10/50/10/10mg)
$163.00
This product name (e.g. GLOW, KLOW, Wolverine) is only an informal catalog nickname, used so researchers can find this blend. It is not a claim of any cosmetic, beauty, skin, anti-aging, or therapeutic benefit. Supplied strictly for laboratory research use only — not for human, veterinary, cosmetic, or therapeutic use.
KPV · GHK-Cu · BPC-157 · TB-500
Four-peptide blend
80 mg combined
A four-peptide research blend combining BPC-157, GHK-Cu, TB-500, and KPV in a single sterile lyophilized vial for in-vitro study.
Tested by Freedom Diagnostics TestingHPLC purity + LC-MS identityLot-matched COA on-site
For research use only. This product is a laboratory research chemical. It is not for human or veterinary use, not a drug, supplement, or food, and not intended to diagnose, treat, cure, or prevent any disease. Sold only to qualified researchers and institutions.
What is the KLOW Quad-Peptide Blend?
KLOW Blend is a research-grade four-peptide blend supplied in a single co-lyophilized vial — BPC-157 (10 mg), GHK-Cu (50 mg), TB-500 (10 mg) and KPV (10 mg), 80 mg combined. The four components span distinct structural classes and non-overlapping pathway layers: BPC-157 for angiogenic and growth-factor signaling, GHK-Cu for copper-mediated extracellular-matrix and collagen biology, TB-500 (Thymosin Beta-4) for actin-driven cell migration, and KPV (the C-terminal α-MSH fragment) for NF-κB and inflammatory-cytokine modulation.
Research areas where laboratories buy KLOW for in vitro work include multi-peptide signaling across angiogenic, anti-inflammatory and tissue-repair pathways, single-peptide versus multi-peptide comparisons on fibroblast migration and ECM organization, NO / VEGFR2 and FAK-paxillin pathway activity, and NF-κB pathway modulation. The material supplied here is research-grade for in vitro laboratory study only.
Every lot, independently verified
Endotoxin (USP <85>)Within limits ✓
Compound information
Chemical & structural reference data — specifications, molecular profile and handling.
Product Specifications
Molecular Profile
Storage & Handling
In solution2–8 °C; aliquot & freeze
KLOW Blend Mechanism of Action
- BPC-157 engages angiogenic and growth-factor signaling — VEGF/VEGFR2, FAK-paxillin, and nitric-oxide pathways in fibroblast and vascular models.
- GHK-Cu chelates Cu²⁺ and modulates collagen, decorin, and matrix-metalloproteinase gene expression in dermal fibroblast cultures.
- TB-500 binds monomeric G-actin via the LKKTETQ motif, modulating the actin pool available for cytoskeletal remodeling and cell migration.
- KPV, the C-terminal α-MSH fragment, modulates NF-κB signaling and inflammatory-cytokine response in cell-based models.
- The four components span distinct structural classes and non-overlapping pathway layers — signaling, ECM remodeling, cytoskeleton, and inflammation.
- Studied as a multi-peptide reference system for how angiogenic, anti-inflammatory, and tissue-repair pathways interact in shared assays.
KLOW Blend Research Applications
- Modeling of multi-peptide signaling across angiogenic, anti-inflammatory, and tissue-repair pathways in in-vitro systems.
- Comparative studies of single-peptide versus multi-peptide activity on fibroblast migration, proliferation, and ECM organization.
- Nitric-oxide (NO), VEGF/VEGFR2, and FAK-paxillin pathway activity in cell-culture models of soft-tissue repair using BPC-157.
- NF-κB pathway modulation and inflammatory-cytokine response in cell-based models using KPV.
- Gene-expression changes in dermal fibroblast cultures exposed to GHK-Cu — collagen, decorin, and matrix-metalloproteinase regulation.
- Actin-binding and cell-migration activity of Thymosin Beta-4 (TB-500) in wound-healing research models.
Why Buy KLOW Blend from Koi Peptides?
- Every batch of Koi KLOW Blend is synthesized and lyophilized in the United States, then released against independent third-party laboratory (Freedom Diagnostics Testing) testing.
- Each lot is tested by HPLC for purity, LC-MS for identity confirmation, and endotoxin assay for sterility readiness.
- The lot ID is printed on every vial and ties back to a public COA library, so researchers can verify documentation before they buy and after the vial arrives.
- Orders placed before 2 PM CT ship the same business day, and shipping is free on orders over $200.
References
The laboratory and preclinical research behind the KLOW components — cited for scientific context.
View all 8 references+
- Sikirić, P., et al. (2018). Stable gastric pentadecapeptide BPC 157 — vascular and organoprotective effects. Current Pharmaceutical Design, 24(18), 1990–2001. doi.org/10.2174/1381612824666180712110447
- Pickart, L., & Margolina, A. (2018). Regenerative and protective actions of the GHK-Cu peptide. International Journal of Molecular Sciences, 19(7), 1987. doi.org/10.3390/ijms19071987
- Pickart, L., et al. (1980). Growth-modulating plasma tripeptide may function by facilitating copper uptake into cells. Nature, 288(5792), 715–717. doi.org/10.1038/288715a0
- Goldstein, A. L., et al. (2005). Thymosin β4: actin-sequestering protein moonlights to repair injured tissues. Trends in Molecular Medicine, 11(9), 421–429. doi.org/10.1016/j.molmed.2005.07.004
- Bock-Marquette, I., et al. (2004). Thymosin β4 activates ILK and promotes cardiac cell migration, survival and repair. Nature, 432(7016), 466–472. doi.org/10.1038/nature03000
- Dalmasso, G., et al. (2008). PepT1-mediated transport of the tripeptide KPV is responsible for reduction of intestinal inflammation. Gastroenterology, 134(1), 166–178. doi.org/10.1053/j.gastro.2007.11.026
- Kannengiesser, K., et al. (2008). Melanocortin-derived tripeptide KPV has anti-inflammatory potential. Inflammatory Bowel Diseases, 14(3), 324–331. doi.org/10.1002/ibd.20453
- Seiwerth, S., et al. (2021). Stable gastric pentadecapeptide BPC 157 and wound healing. Frontiers in Pharmacology, 12, 627533. doi.org/10.3389/fphar.2021.627533
Regulatory Status
FDA, WADA anti-doping, and compounding status — provided for research context.FDA StatusNone of KLOW Blend’s four components — BPC-157, GHK-Cu, TB-500, or KPV — is approved by the FDA as a drug for any indication. The research-grade blend supplied by Koi Peptides is synthesized independently for in vitro laboratory research only — not formulated, packaged, or labeled for human use, not equivalent to or a substitute for any approved drug product, and not authorized for any human or veterinary indication.
WADA Anti-Doping StatusThe TB-500 component (thymosin β-4) is a prohibited substance under WADA Section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times. Athletes subject to anti-doping rules should treat KLOW Blend accordingly and confirm current status with their governing body. The other components are not specifically named on the current Prohibited List; the presence of TB-500 makes the blend relevant under S2.
Compounding Pharmacy StatusKoi Peptides is a chemical research supplier — not a compounding pharmacy or outsourcing facility under sections 503A or 503B of the Federal Food, Drug, and Cosmetic Act — and supplies no compounded preparations of any kind. KLOW Blend is research-grade material for in vitro laboratory study, not a compounded preparation for human use.
DisclaimerFor research use only. Not for human or veterinary use. KLOW Blend is supplied to qualified research professionals for in vitro laboratory study. It has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease. Koi Research Labs LLC is a chemical supplier, not a compounding pharmacy under 503A nor an outsourcing facility under 503B of the Federal Food, Drug, and Cosmetic Act. By purchasing, the buyer agrees this material will not be introduced into humans or animals. Misuse may violate federal, state, or local laws.
Be the first to review “KLOW Blend 80mg: KPV/GHK-Cu/BPC-157/TB-500 (10/50/10/10mg)”
Related products
Reviews
There are no reviews yet.